However, interleukin-2 (IL-2)- and interferon-α (IFN-α)-based immunotherapy can induce durable tumour regression in 5–10% of patients with mRCC (Minasian et al, 1993; Rosenberg, 2001). This evidence concerns the gene IFNA2 and neoplasm.